The only thing mentioning these two together is here with a pay wall. Probably doesn’t tell us anything new.

https://academic.oup.com/jac/advance-article/...chresult=1

“ Many antiretrovirals now have the potential to be administered in these ways, such as cabotegravir, rilpivirine, leronlimab, islatravir ...”

Maybe multi drug resistant for long acting but I’m assuming they aren’t targeting that just yet. They probably just want to use any drug that can extend CAB to that 4/6 month mark.